Biomedical Catalyst – Antibody Directed Phototherapy for Oesophageal Adenocarcinoma

食道癌正在迅速上升，是男性第四大癌症杀手。该项目支持将PhotoBiotics的专有OptiLink技术和自己的药物与帝国理工学院和伦敦大学学院国家医学激光中心的专家结合起来，开发一种治疗癌症的新型抗体导向光疗(ADP)药物。这些药物几乎没有副作用，肿瘤不会对它们产生抗药性。我们已经确定了一个经过临床验证的靶点，并有初步数据表明，我们可以解决食道癌的这个问题。光生物公司将监督药物的制造和测试，帝国理工学院将帮助产生功能数据，伦敦大学学院将使用他们建立的模型治疗肿瘤。如果成功，这样的资金将导致制药行业对将其用于临床试验的主要兴趣。

Oesophageal Cancer is rapidly rising and is the 4th largest cancer killer in men. This project supports combining PhotoBiotics' proprietary OptiLink technology and its own drugs with experts from Imperial College and University College London National Medical Laser Centre to develop a novel antibody-directed phototherapy (ADP) drug to treat cancer. These drugs have few side effects and tumours cannot develop drug resistance to them. We have identified a clinically-validated target and have preliminary data to show that we can tackle this for Oesophageal Cancer. Photobiotics will oversee the manufacture and testing of the drug, Imperial College will help to generate functional data and UCL will treat tumours using their established models. If successful, thus funding will lead to major interest from the pharmaceutical industry to take this into clinical trials.